OverviewSuggest Edit

Kuros Biosciences engages in the discovery, development, and commercialization of biopharmaceutical products for the treatment and prevention of chronic diseases internationally. Its sealants pipeline products include Neuroseal EU and US for the treatment of dural sealant cranial. The Сompany's synthetic orthobiologics pipeline products comprise MagnetOs Granules EU and MagnetOs Putty EU for the treatment of orthopedics, spinal, and dental problems; and MagnetOs Granules US and MagnetOs Putty US for the treatment of spinal fusion.
TypePublic
Founded2000
HQSchlieren, CH
Websitekuros.ch

Latest Updates

Employees (est.) (Feb 2019)35(+25%)
Share Price (May 2020)CHF2.1 (-5%)

Key People/Management at Kuros Biosciences

Joost de Bruijn

Joost de Bruijn

Chief Executive Officer, Director
Michael Grau

Michael Grau

Chief Financial Officer
Alistair Irvine

Alistair Irvine

Chief Business Officer
Pascal Longlade

Pascal Longlade

Chief Medical Officer
Phillippe Saudan

Phillippe Saudan

Chief Development Officer
Scott Bruder

Scott Bruder

Non-Executive Director
Show more

Kuros Biosciences Office Locations

Kuros Biosciences has offices in Schlieren and Bilthoven
Schlieren, CH (HQ)
25 Wagistrasse
Bilthoven, NL
Professor Bronkhorstlaan 10, G 48
Show all (2)

Kuros Biosciences Financials and Metrics

Kuros Biosciences Revenue

Market capitalization (27-Apr-2020)

46.0m

Closing stock price (27-Apr-2020)

2.0
Kuros Biosciences's current market capitalization is CHF46 m.
Show all financial metrics

Kuros Biosciences Online and Social Media Presence

Embed Graph

Kuros Biosciences News and Updates

Kuros Biosciences announces full commercial launch of MagnetOs™ and exhibitor status at North American Spine Society 34th Annual Meeting

SCHLIEREN (ZURICH), Switzerland, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Kuros Biosciences, a leader in next generation bone graft technologies, today announces the full commercial launch of MagnetOs™ and the company’s first attendance as an exhibitor at NASS, the world’s largest spine meeting and exhi…

Kuros Biosciences Announces U.S. FDA approval of IND Application to Initiate Fibrin-PTH Phase 2a Clinical Trial in Spinal Fusion

SCHLIEREN (ZURICH), Switzerland, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Kuros Biosciences, a leader in next generation bone graft technologies, today announces that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to initiate a Phase 2a clinical t…

Kuros Biosciences Enters Convertible Bond Financing Agreement For Up To CHF 5 Million

SCHLIEREN (ZURICH), Switzerland, April 09, 2019 (GLOBE NEWSWIRE) -- Kuros Biosciences (SIX: KURN) today announced that it has entered into a convertible bond financing agreement with Nice & Green S.A. for up to a maximum of CHF 5 million.
Show more

Kuros Biosciences Frequently Asked Questions

  • When was Kuros Biosciences founded?

    Kuros Biosciences was founded in 2000.

  • Who are Kuros Biosciences key executives?

    Kuros Biosciences's key executives are Joost de Bruijn, Michael Grau and Alistair Irvine.

  • How many employees does Kuros Biosciences have?

    Kuros Biosciences has 35 employees.

  • Who are Kuros Biosciences competitors?

    Competitors of Kuros Biosciences include Sorrento Therapeutics, Pernix Therapeutics and Alnylam Pharmaceuticals.

  • Where is Kuros Biosciences headquarters?

    Kuros Biosciences headquarters is located at 25 Wagistrasse, Schlieren.

  • Where are Kuros Biosciences offices?

    Kuros Biosciences has offices in Schlieren and Bilthoven.

  • How many offices does Kuros Biosciences have?

    Kuros Biosciences has 2 offices.